APLS - Apellis Pharmaceuticals

-

$undefined

N/A

(N/A)

Apellis Pharmaceuticals NASDAQ:APLS Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology.

Location: 100 Fifth Avenue, Massachusetts, 02451, United States | Website: apellis.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

3.581B

Cash

403.7M

Avg Qtr Burn

-51.28M

Short % of Float

24.56%

Insider Ownership

13.98%

Institutional Own.

93.48%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
SYFOVRE™(Intravitreal pegcetacoplan) Details
Age-related macular degeneration, Geographic atrophy

Approved

Quarterly sales

Empaveli (systemic pegcetacoplan) (APL-2) Details
Paroxysmal nocturnal hemoglobinuria

Approved

Quarterly sales

Systemic pegcetacoplan (APL-2) Details
Immune complex membranoproliferative glomerulonephritis, C3 Glomerulopathy

sNDA

Submission

Systemic pegcetacoplan (APL-2) Details
Hematopoietic stem cell transplantation thrombotic microangiopathies

Phase 2

Data readout

Systemic pegcetacoplan (APL-2) Details
Immune complex membranoproliferative glomerulonephritis, C3 Glomerulopathy

Phase 2

Update

APL-3007 (small interfering RNA silencing C3) Details
Autoimmune disease, Inflammatory disease

Phase 1

Data readout

Systemic pegcetacoplan (APL-2) Details
Amyotrophic lateral sclerosis

Failed

Discontinued

Failed

Discontinued

Intravenous APL-9 Details
ARDS (Acute respiratory distress syndrome), TMA (Thrombotic microangiopathies)

Failed

Discontinued